In a related matter:
Vitamin D supplementation has been suggested as a means to lower risk of major cardiac events. A large trial of high-dose vitamin D in Australia has just been published. From Medpage Today:
“Monthly super-sized vitamin D supplements failed to significantly reduce major cardiovascular events in older adults, the Australian D-Health Trial found.”
“Over up to 5 years of treatment, incident myocardial infarction (MI), stroke, and coronary revascularization turned up in 6% of the vitamin D group and 6.6% of the placebo group (HR 0.91, 95% CI 0.81-1.01), and that hazard ratio didn’t budge over time.”
“There was no effect modification by age, sex, or body mass index, reported Rachel Neale, PhD, of Queensland Institute of Medical Research’s Berghofer Medical Research Institute in Herston, Australia, and colleagues.”
https://www.bmj.com/content/381/bmj-2023-075230).
"However, some individual components of the primary outcome appeared more indicative of a clinical benefit for the monthly 60,000 IU dose of vitamin D supplementation:
- Myocardial infarction (HR 0.81, 95% CI 0.67-0.98)
- Coronary revascularisation (HR 0.89, 95% CI 0.78-1.01)
- Stroke (HR 0.99, 95% CI 0.80-1.23)
“Also potentially redeeming was a signal that there was better reduction in cardiovascular events in vitamin D users who had been taking statins or other cardiovascular medications at baseline (HR 0.84, 95% CI 0.74-0.97), though the P-value for interaction was not significant.”
“Vitamin D supplementation might reduce the incidence of major cardiovascular events, although the absolute risk difference was small and the confidence interval was consistent with a null finding. These findings could prompt further evaluation of the role of vitamin D supplementation, particularly in people taking drugs for prevention or treatment of cardiovascular disease,” Neale and colleagues concluded."